(Q35182951)

7 August 2017

1 reference

title

The current status of aromatase inhibitors in the management of breast cancer (English)

1 reference

7 August 2017

Michael Baum

1

1 reference

7 August 2017

Aman Buzdar

series ordinal

2

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Surgical Clinics of North America

7 August 2017

published in

1 reference

7 August 2017

volume

83

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

973-994

1 reference

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Influence of Synthetic Oestrogens on Advanced Malignant Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

The Use of Testosterone Propionate in the Treatment of Advanced Carcinoma of the Breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Preliminary trial of aminoglutethimide in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Steroidal side effects of exemestane

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Letrozole: which dose to be used?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Tamoxifen and endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Gynaecological monitoring during tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Endometrial lesions in patients undergoing tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Hysteroscopic follow-up during tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Tamoxifen and risk of idiopathic venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Tamoxifen and contralateral breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Breast cancer prevention: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

Future possibilities in the prevention of breast cancer: breast cancer prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

How are bisphosphonates used today in breast cancer clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900031-8

7 January 2021

10.1016/S0039-6109(03)00031-8

Identifiers

DOI

1 reference

7 August 2017

1 reference